Danaher Corporation (DHR) Shares Bought by Raymond James Financial Services Advisors Inc.
Raymond James Financial Services Advisors Inc. grew its position in shares of Danaher Corporation (NYSE:DHR) by 1.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 70,541 shares of the conglomerate’s stock after buying an additional 1,193 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in Danaher Corporation were worth $6,051,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Palisade Asset Management LLC lifted its holdings in shares of Danaher Corporation by 40.0% during the 3rd quarter. Palisade Asset Management LLC now owns 17,490 shares of the conglomerate’s stock valued at $1,500,000 after buying an additional 5,000 shares during the period. Broderick Brian C lifted its holdings in shares of Danaher Corporation by 8.8% during the 3rd quarter. Broderick Brian C now owns 61,810 shares of the conglomerate’s stock valued at $5,301,000 after buying an additional 4,995 shares during the period. Hemenway Trust Co LLC lifted its holdings in shares of Danaher Corporation by 20.9% during the 3rd quarter. Hemenway Trust Co LLC now owns 149,266 shares of the conglomerate’s stock valued at $12,804,000 after buying an additional 25,812 shares during the period. Delaney Dennis R lifted its holdings in shares of Danaher Corporation by 12.9% during the 3rd quarter. Delaney Dennis R now owns 6,045 shares of the conglomerate’s stock valued at $518,000 after buying an additional 690 shares during the period. Finally, Notis McConarty Edward lifted its holdings in shares of Danaher Corporation by 2.9% during the 3rd quarter. Notis McConarty Edward now owns 26,075 shares of the conglomerate’s stock valued at $2,237,000 after buying an additional 730 shares during the period. 75.56% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Danaher Corporation (NYSE DHR) opened at $93.68 on Tuesday. Danaher Corporation has a 12 month low of $76.27 and a 12 month high of $93.86. The company has a quick ratio of 1.00, a current ratio of 1.43 and a debt-to-equity ratio of 0.42. The stock has a market capitalization of $65,020.00, a price-to-earnings ratio of 23.99, a price-to-earnings-growth ratio of 2.22 and a beta of 1.02.
Danaher Corporation (NYSE:DHR) last issued its quarterly earnings results on Thursday, October 19th. The conglomerate reported $1.00 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.95 by $0.05. Danaher Corporation had a return on equity of 11.29% and a net margin of 13.36%. The business had revenue of $4.53 billion during the quarter, compared to analyst estimates of $4.47 billion. During the same quarter in the prior year, the business posted $0.87 EPS. Danaher Corporation’s revenue for the quarter was up 9.6% compared to the same quarter last year. equities analysts expect that Danaher Corporation will post 3.99 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, October 27th. Stockholders of record on Friday, September 29th were given a dividend of $0.14 per share. The ex-dividend date was Thursday, September 28th. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.60%. Danaher Corporation’s payout ratio is 16.67%.
In other news, CAO Robert S. Lutz sold 11,189 shares of the firm’s stock in a transaction dated Monday, October 23rd. The stock was sold at an average price of $91.66, for a total transaction of $1,025,583.74. Following the completion of the transaction, the chief accounting officer now owns 18,314 shares in the company, valued at $1,678,661.24. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Thomas Patrick Joyce, Jr. sold 125,989 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $92.64, for a total value of $11,671,620.96. Following the transaction, the chief executive officer now owns 271,737 shares of the company’s stock, valued at approximately $25,173,715.68. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 317,498 shares of company stock valued at $28,838,801. Company insiders own 12.20% of the company’s stock.
Several equities analysts have recently weighed in on the company. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $83.00 price target on shares of Danaher Corporation in a report on Tuesday, September 26th. Jefferies Group LLC restated a “buy” rating and issued a $95.00 price objective on shares of Danaher Corporation in a research note on Friday, August 4th. BidaskClub lowered Danaher Corporation from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 1st. Zacks Investment Research lowered Danaher Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, July 27th. Finally, Robert W. Baird upped their price objective on Danaher Corporation from $87.00 to $97.00 and gave the stock an “outperform” rating in a research note on Friday, October 20th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $93.31.
About Danaher Corporation
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Stock Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related stocks with our FREE daily email newsletter.